Post Subject #169   9/14 MannKind Puts Focus On Pipeline TREND1 09/14/17 12:28:32 PM #168   9/13 MannKind: Their Technosphere Drug Delivery System - TREND1 09/13/17 11:18:29 AM #167   9/11 MannKind Corporation's (MNKD) CEO Michael Castagna Presents TREND1 09/11/17 06:50:15 PM #166   9/9 MannKind - Afrezza Scripts Finish August Flat TREND1 09/09/17 11:34:15 AM #165   9/1 MannKind: Afrezza Sales Bring In More Dollars; TREND1 09/01/17 03:11:52 PM #164   8/25 MannKind - Scripts, Marketing, And Clinical Trials TREND1 08/25/17 04:11:29 PM #163   8/18 MannKind - Scripts Rise, But Not Enough TREND1 08/18/17 01:02:53 PM #162   8/8 Micron Technology Is Looking Cheap TREND1 08/08/17 11:27:06 AM #161   8/8 MannKind's (MNKD) CEO Michael Castagna On Q2 TREND1 08/08/17 11:24:54 AM #160   8/7 Apple Needs Micron Technology TREND1 08/07/17 11:37:49 AM #159   8/7 MannKind - Afrezza Scripts Dip With Quarterly TREND1 08/07/17 11:08:01 AM #158   8/3 Micron: A Sudden Drop Flags Trouble TREND1 08/03/17 11:39:34 AM #157   MNKD CCI 10 NO STOPS TREND1 08/02/17 03:04:37 PM #155   8/1 Citi advises to buy on Micron weakness TREND1 08/01/17 11:10:35 AM #154   7/31 MannKind: Afrezza Sales Spike, Giving Cautious Optimism TREND1 07/31/17 10:39:22 AM #153   Rite Aid Is Better Off Dead TREND1 07/30/17 09:38:46 PM #152   MNKD CCI 10 TREND1 07/30/17 04:04:05 PM #151   7/25 MannKind: Assessing The Insurance Landscape For Afrezza TREND1 07/25/17 10:55:53 PM #150   7/21 MannKind: Afrezza Scripts Stable At A Bit TREND1 07/21/17 04:30:53 PM #149   7/20 MannKind - Afrezza Television Ad Debuts - TREND1 07/20/17 05:09:36 PM #148   7/18 Earnings Preview: Valeant Pharmaceuticals TREND1 07/18/17 10:45:53 AM #147   7/17 Valeant: At Worst, A Good Catalyst Play TREND1 07/17/17 06:08:48 PM #146   7/17 Mixed Feelings About The $190 Million Obagi Sale TREND1 07/17/17 03:12:47 PM #145   7/14 MannKind - Afrezza Scripts Remain Above 300 TREND1 07/14/17 03:11:47 PM #143   7/12 Arena Announces Prospectus To Sell $150 Million TREND1 07/12/17 11:00:06 AM #142   7/11 So Many Promises And Now We Are TREND1 07/11/17 09:32:33 PM #141   7/11 JohnnyMoneymaker TREND1 07/11/17 03:47:14 PM #140   7/11 Arena Announces Positive Clinical Trial Results TREND1 07/11/17 10:40:27 AM #139   7/10 Spencer Osborne's Blog TREND1 07/10/17 05:51:20 PM #138   7/7 MannKind: Weekly Afrezza Scripts Leveling Off Above 300 TREND1 07/07/17 03:37:09 PM #136   7/2 A Micron Super Cycle? TREND1 07/02/17 09:21:42 PM #135   7/2 MannKind - Afrezza Scripts Come Back Down TREND1 07/02/17 10:56:54 AM #134   6/30 MannKind - Afrezza Scripts Come Back Down TREND1 06/30/17 11:58:52 AM #133   6/29 Micron Q3 beats estimates, OCF doubled on TREND1 06/29/17 04:52:17 PM #132   6/29 MannKind Renegotiates Debt Payment To Deerfield TREND1 06/29/17 02:41:59 PM #130   6/29 MannKind Maxes Out Its Last Credit Card TREND1 06/29/17 11:41:04 AM #128   6/27 Micron: I'm Betting Big TREND1 06/27/17 04:17:35 PM #127   6/26 Rite Aid: Merger Is Sunk TREND1 06/26/17 03:07:09 PM #126   6/25 Fred's and Rite Aid keep racing higher TREND1 06/26/17 03:04:33 PM #125   6/23 MannKind: Afrezza Sales See Best Result In TREND1 06/23/17 12:58:36 PM #124   6/19 MannKind: Afrezza Scripts Above 300 - Can TREND1 06/19/17 10:15:14 AM #123   ism data from WHS TREND1 06/16/17 01:33:28 PM #122   Shorts lose battles, but rarely lose the war TREND1 06/16/17 12:56:12 PM #121   Largest 50 companies by market cap TREND1 06/14/17 11:44:35 PM #120   6/14 Cash flow positive by Q4 2017 TREND1 06/14/17 05:18:01 PM #119   6/13 MannKind - Afrezza Adverse Events Data Q1 2017 TREND1 06/13/17 02:28:25 PM #118   6/13 MannKind Scripts Not Helping Cash Situation TREND1 06/13/17 01:46:04 PM #117   6/8 I do not see AFREZZA drop out TREND1 06/08/17 12:42:07 PM #116   6/6 The rejection rate for AFREZZA is 95.5 TREND1 06/06/17 10:51:26 PM #115   5/30/17 Hypi sees a buy out by AMGN TREND1 06/06/17 10:44:05 PM Post Subject

© 2017 InvestorsHub.Com, Inc.